HIV-specific immunity during structured antiviral drug treatment interruption

Vaccine

Volumn 21, Issue 11-12, 2003, Pages 1066-1071

  Moss, Ronald B ^a   Brandt, Carolyn ^b   Giermakowska, Wieslawa K ^a   Savary, Jay R ^a   Theofan, Georgia ^a   Zanetti, Maurizio ^c   Carlo, Dennis J ^a   Wallace, Mark R ^b  

^a Orchestra Therapeutics Inc   (United States)

^b NAVAL MEDICAL CENTER SAN DIEGO   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Beta chemokine; CD4; CD8

Indexed keywords

GAG PROTEIN; GAMMA INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MACROPHAGE INFLAMMATORY PROTEIN 1BETA;

ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; HELPER CELL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; PRIORITY JOURNAL; TREATMENT OUTCOME; VIREMIA; VIRUS IMMUNITY;

AIDS VACCINES; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; COMBINED MODALITY THERAPY; DRUG ADMINISTRATION SCHEDULE; HIV CORE PROTEIN P24; HIV INFECTIONS; HIV-1; HUMANS; IMMUNITY, CELLULAR; IMMUNOTHERAPY, ACTIVE; INTERFERON TYPE II; LYMPHOCYTE ACTIVATION; MACROPHAGE INFLAMMATORY PROTEIN-1; T-LYMPHOCYTES, HELPER-INDUCER; VIRAL LOAD; VIREMIA;

EID: 0037424115     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(02)00610-2     Document Type: Article

References (20)

1. Altfeld M., Walker B.D. Less is more? STI in acute and chronic HIV-1 infection. Nat. Med. 7:2001;881-884.
2. Lori F., Lisziewicz J. Structured treatment interruptions for the management of HIV infection. JAMA. 6:2001;2981-2987.
3. Rosenberg E.S., Billingsley J.M., Caliendo A.M.et al. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science. 278:1997;1447-1450.
4. Oxenius A., Price D.A., Easterbrook P.J.et al. Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8+ and CD4+ T-lymphocytes. Proc. Natl. Acad. Sci. U.S.A. 97:2000;3382-3387.
5. Malhotra U., Berrey M.M., Huang Y.et al. Effect of combination antiretroviral therapy on T-cell immunity in acute human immunodeficiency virus type 1 infection. J. Infect. Dis. 181:2000;121-131.
6. Rosenberg E.S., Altfeld M., Poon S.H.et al. Immune control of HIV-1 after early treatment of acute infection. Nature. 407:2000;523-526.
7. Lori F., Lewis M.G., Xu J.et al. Control of SIV rebound through structured treatment interruptions during early infection. Science. 290:2000;1591-1593.
8. McNeil A.C., Shupert W.L., Iyasere C.A.et al. High-level HIV-1 viremia suppresses viral antigen-specific CD4(+) T cell proliferation. Proc. Natl. Acad. Sci. U.S.A. 98:2001;13878-13883.
9. Ruiz L., Carcelain G., Martinez-Picado J.et al. HIV dynamics and T-cell immunity after three structured treatment interruptions in chronic HIV-1 infection. AIDS. 15:2001;F19-27.
10. Garcia F., Plana M., Ortiz G.M.et al. The virological and immunological consequences of structured treatment interruptions in chronic HIV-1 infection. AIDS. 15:2001;F29-40.
11. Prior C.P., Gore R., Harter J.et al. Inactivation and purification of human immunodeficiency virus-1 as antigen for the treatment of HIV-1 infection. BioPharmaceutics. 9:1996;22-34.
12. Prior C., Bay P., Ebert B.et al. Process development for the manufacture of inactivated HIV-1. Pharma. Technol. 19:1995;30-52.
13. Choi D.J., Dube S., Spicer T.P., Slade H.B., Jensen F.C., Poiesz B.J. HIV type 1 isolate HZ321 the strain used to make a therapeutic HIV type 1 immunogen is intersubtype recombinant. AIDS Res. Hum. Retroviruses. 13:1997;357-361.
14. Getchell J.P., Hicks D.R., Srinivasan A.et al. Human immunodeficiency virus isolated from a serum sample collected in 1976 in central Africa. J. Infect. Dis. 156:1987;833-837.
15. LoGrippo G.A. Investigations of the use of beta-propiolactone in virus inactivation. Ann. N.Y. Acad. Sci. 83:1960;578-594.
16. Kitchen A.D., Mann G.F., Harrison J.F., Zuckerman A.J. Effect of gamma irradiation on the human immunodeficiency virus and human coagulation proteins. Vox. Sang. 56:1989;223-229.
17. Moss R.B., Webb E., Giermakowska W.K.et al. HIV-1 specific CD4 helper function in chronic HIV-1 infection on antiviral drug therapy as measured by ELISPOT after treatment with an inactivated gp120 depleted HIV-1 in Incomplete Freund's Adjuvant. J. Acquired Immune Defic. Syndr. 24:2000;264-269.
18. Kalams S.A. Association between virus-specific cytotoxic T-lymphocyte and helper responses in human immunodeficiency virus type 1 infection. J. Virol. 73:1999;6715-6720.
19. Moss R.B., Trauger R.T., Giermakowska W.K.et al. Effect of immunization with an inactivated gp120-depleted HIV-1immunogen on β-chemokine and cytokine production in subjects with HIV-1 infection. J. Acquired Immune Defic. Syndr. Hum. Retrovirol. 14:1997;343-350.
20. Maecker H.T., Dunn H.S., Suni M.A. Use of overlapping peptide mixtures as antigens for cytokine flow cytometry. J. Immunol. Methods. 255:2001;27-40.